ClinicalTrials.gg

Dementia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,375 studies for Dementia across more than 10 countries. 574 are recruiting or about to start. 1,000 of them are mainly about Dementia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 11 narrower conditions too, such as Alzheimer Disease: 6,010 studies, 1,428 open.

ClinicalTrials.gov finds 6,713 studies for Dementia. How that becomes 2,375 here

This page counts the studies the registry files under Dementia, and those it files under no condition that list Dementiathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 6,713Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −3,569Filed under a narrower condition, counted on its own pageAlzheimer Disease 2,945 · Huntington Disease 263 · Lewy Body Disease 99 · Frontotemporal Dementia 96 · Dementia, Vascular 46 · AIDS Dementia Complex 38 · 5 more
  3. −104List Dementia as a condition, but the registry did not file them under itMost often written as “Mild Dementia” (20), “Delirium, Dementia, Amnestic, Cognitive Disorders” (8), and “Behavioral and Psychiatric Symptoms of Dementia” (6). The registry filed them under other conditions only, most often Cognitive Dysfunction (36) and Parkinson Disease (13).
  4. −665Match it another way194 name it in the title, 38 in a keyword, and 433 by a synonym or other text the search reads.
  5. 2,375The count on this page110 of them list Dementia in their own words; the registry filed them under no condition.

Status

Completed
1,286
Recruiting
383
Status unknown
228
Not yet recruiting
137
Active, not recruiting
130
Terminated
101

Phase

Phase 2
243
Phase 3
151
Phase 1
107
Phase 4
75
Early Phase 1
9

Where

United States
1,050
Canada
192
United Kingdom
178
France
128
Spain
114
Taiwan
105

Who develops what

Add Dementia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 18 programs from 15 companies, 1 with this as their studies’ main aim; 6 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Bristol-Myers Squibb, Eli Lilly and Alnylam Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DexamethasoneRecent, limited
Evidence
  • NCT05738486 · Eli Lilly and Company · Phase 3 · live · background · “Dexamethasone” · registered Feb 2023
AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016)11 study
DonepezilRecent, limited
Evidence
  • NCT05811000 · Mediforum Ltd., Co. · Phase 3 · comparator · “Donepezil” · registered Mar 2023
  • NCT01466088 · Targacept Inc. · Phase 2 · comparator · “Donepezil” · registered Nov 2011
  • NCT00501111 · AstraZeneca · Phase 2 · comparator · “Donepezil” · registered Jul 2007
Eisai Co., Ltd.47% of its industry studiesUS: off-patent, 17 generics marketed11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 18 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 1 Dec 2026 est.florzolotau F-18 · JYAMS PET Research & Development Limited · Phase 3 named, not the main aimNCT07422857 Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function — primary endpoint: Evaluate the effectiveness of visual reading results of [18 F]-APN-1607 injection PET imaging in detecting tau NFTs(Neurofibrillary Tangles) · 316 enrolled
  • 29 Dec 2026 est.N-Acetylcysteinamide · Arctic Therapeutics · Phase 2 registry mapping onlyNCT07716865 Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA) — primary endpoint: Incidence of Treatment-Emergent Adverse Events · 15 enrolled
  • 31 Dec 2026 est.ONO-2020 · Ono Pharmaceutical Co. Ltd · Phase 2 named, not the main aimNCT06803823 A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia — primary endpoint: Change in CMAI score from baseline · 90 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Dementia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimuscarinics 3 open · Statins 2 open · Tyrosine kinase inhibitors (TKIs) 1 open · NSAIDs 1 open · Cholinesterase inhibitors 54

Coming up

216studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger. 16 (4%) take children under 18. 2 (1%) are for women only and 1 (<1%) for men only; 164 (43%) take healthy volunteers.

Recruiting studies that take each age, of 383
AgeWomenMen
1015 (4%)15 (4%)
18127 (33%)127 (33%)
30152 (40%)152 (40%)
40174 (45%)173 (45%)
50243 (63%)242 (63%)
65373 (97%)373 (97%)
75369 (96%)369 (96%)
85338 (88%)338 (88%)

Across all 2,375 studies, recruiting or not: 5% stop at 75 or younger and 2% at 65; 9% take children; 1% are for women only and 1% for men only; 35% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Dementia studies take

Of 83 phase 2 interventional studies under Dementia, half reached primary completion within 38 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 125 mo11–42 · 37 studies——
Phase 1/249 mo24–68 · 17 studies——
Phase 238 mo23–61 · 83 studies26 mo17–39 · 41 studies59 mo38–78 · 42 studies
Phase 2/356 mo41–59 · 20 studies——
Phase 341 mo30–60 · 34 studies——
Phase 459 mo29–80 · 20 studies——
Interventional, no phase25 mo11–43 · 907 studies17 mo11–35 · 46 studies25 mo11–44 · 861 studies
Observational65 mo29–188 · 293 studies—74 mo32–202 · 271 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered20

Show 15 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,375. Browse all 2,375 → or search them.